two
crucial
consider
gene
therapi
relat
gene
deliv
express
deliv
simplest
form
gene
therapi
process
either
defect
miss
gene
replac
new
function
host
cell
introduc
purpos
genet
materi
coupl
addit
regulatori
sequenc
eg
promot
enhanc
packag
insid
gene
deliveri
vehicl
enabl
transfer
express
intend
gene
product
insid
cell
fig
although
conceptu
straightforward
effici
express
foreign
gene
critic
aspect
success
vivo
gene
therapi
first
step
gene
therapi
involv
gene
deliveri
facilit
express
therapeut
gene
interior
cell
simplest
method
direct
introduct
therapeut
dna
target
cell
physic
ie
electropor
chemic
techniqu
ie
lipofect
approach
still
remain
limit
applic
rel
ineffici
use
certain
tissu
requir
larg
amount
dna
furthermor
among
sever
barrier
success
gene
deliveri
foreign
gene
andor
vector
use
deliv
trigger
rang
immun
respons
howev
sometim
immun
respons
har
behind
concept
use
gene
therapi
vaccin
ie
dna
vaccin
next
difficulti
foreign
genet
materi
within
cell
must
escap
intracellular
degrad
enter
nucleu
express
fig
therefor
gene
deliveri
system
vector
design
protect
genet
materi
ideal
vector
need
meet
three
criteria
protect
transgen
degrad
nucleas
extracellular
matrix
bring
transgen
across
plasma
membran
nucleu
target
cell
detriment
effect
current
vector
gene
transfer
classifi
two
categori
viral
nonvir
five
glioma
gene
therapi
approach
current
explor
prodrug
activ
gene
therapi
also
call
suicid
gene
therapi
chemotherapysensit
gene
therapi
genedirect
enzym
prodrug
therapi
transfer
tumor
suppressor
gene
cell
cycl
modul
genet
immun
modul
antiangiogen
gene
therapi
oncolyt
virus
ov
prodrugactiv
approach
commonli
use
techniqu
clinic
trial
brain
tumor
involv
transduc
tumor
cell
gene
encod
enzym
metabol
nontox
prodrug
toxic
form
herp
simplex
viru
type
thymidin
kinas
thymidin
kinas
hsvtk
enzym
metabol
nontox
nucleosid
analog
ganciclovir
gcv
acyclovir
valacyclovir
vcv
cytotox
molecul
gcv
metabolit
incorpor
dna
caus
dna
elong
termin
subsequ
caus
cell
death
effect
gcv
limit
dna
primarili
target
mitot
cell
much
like
phasespecif
chemotherapeut
agent
also
affect
abil
dna
repair
dna
polymeras
thu
theoret
could
also
affect
quiescent
cell
damag
dna
vivo
efficaci
demonstr
multipl
anim
studi
furthermor
preclin
experi
demonstr
mark
tumor
elimin
despit
gene
transfer
small
fraction
tumor
cell
cytotox
effect
transduc
cell
adjac
nontransduc
cell
term
bystand
effect
bystand
effect
mediat
mainli
transfer
toxic
phosphoryl
form
gcv
nontransduc
cell
presum
via
gap
junction
anoth
presum
mechan
contribut
bystand
effect
target
mitot
activ
endotheli
cell
tumor
vessel
immuneassoci
respons
nonhuman
protein
hsvtk
lead
diffus
cell
death
affect
neighbor
nontransduc
cell
also
suggest
addit
bystand
effect
tumor
cell
transduc
express
hsvtk
treat
antivir
agent
acyclovir
display
enhanc
sensit
radiat
cultur
vivo
possibl
explan
radiat
enhanc
could
dna
incorpor
acyclovir
may
suscept
radiationinduc
strand
breakag
andor
acyclovir
might
sensit
cell
inhibit
polymeras
activ
requir
repair
radiationinduc
dna
damag
hsvtk
gene
therapi
approach
test
human
glioma
trial
phase
iii
use
rv
vector
recent
adenoviru
av
vector
fact
phase
iii
trial
europ
israel
recent
complet
sponsorship
british
biotechnolog
ventur
ark
therapeut
avhsvtk
vector
gcv
provid
patient
newli
diagnos
glioblastoma
gbm
applic
standard
therapi
radiat
andor
temozolomid
interim
result
trial
avail
compani
websit
wwwarktherapeuticscommainproduct
php
take
advantag
possibl
synergi
radiationinduc
damag
dna
inabl
dna
incorpor
vcv
metabolit
repair
recent
complet
phase
clinic
trial
patient
newli
diagnos
malign
glioma
avhsvtk
vcv
use
conjunct
radiat
chiocca
et
al
unpublish
cytosin
agent
use
treat
fungal
infect
candida
albican
prodrug
convert
activ
agent
cytosin
deaminas
cd
uniqu
express
certain
fungi
bacteria
nontox
human
cell
lack
cd
use
treat
cancer
like
colon
pancreat
breast
cancer
toxic
effect
mediat
intracellular
metabolit
caus
dna
strand
breakag
lead
cell
death
two
preclin
studi
glioblastoma
use
adenovir
vector
carri
cd
gene
demonstr
promis
result
howev
clinic
trial
brain
tumor
use
gene
transfer
strategi
far
cytochrom
cyclophosphamid
cpa
prodrug
activ
liverspecif
enzym
cytochrom
famili
activ
form
cpa
ie
phosphoramid
mustard
alkyl
agent
gener
dna
cross
link
consecut
dna
strand
break
efficaci
cpa
treat
brain
tumor
limit
fact
although
cpa
cross
bloodbrain
barrier
activ
metabolit
poorli
transport
across
bloodbrain
barrier
rat
cytochrom
activ
cpa
high
effici
gene
therapi
nucleu
viral
dna
becom
extrachromosom
gene
express
ensu
gene
becom
transcrib
mrna
mrna
becom
protein
desir
therapeut
effect
occur
case
desir
therapeut
effect
eg
cell
death
tumor
cell
caus
apoptosi
introduct
proapoptot
gene
exampl
use
activ
cpa
design
primarili
use
brain
tumor
malign
readi
access
activ
metabolit
cpa
implant
express
rv
vector
shown
induc
regress
glioma
anim
studi
replac
part
genom
gene
led
design
vector
kill
tumor
cell
three
mode
use
viral
oncolysi
render
infect
cell
sensit
cpa
render
infect
cell
sensit
gcv
anim
studi
use
subcutan
tumor
establish
glioma
cell
line
immunodefici
mice
show
tumor
regress
anim
treat
cpa
gcv
current
clinic
trial
brain
tumor
conduct
advanc
understand
underli
molecular
genet
mechan
glioma
provid
ration
framework
develop
new
treatment
tumor
suppressor
protein
regul
cellcycl
progress
apoptosi
respons
mani
extern
insult
eg
dna
damag
oncogen
mutat
mutat
gene
result
loss
function
common
astrocytoma
also
associ
tumor
progress
lowgrad
astrocytoma
glioblastoma
accordingli
gene
becam
attract
candid
gene
transfer
attempt
restor
cell
cycl
regul
cell
induc
apoptosi
even
tumor
intact
function
gene
caus
enhanc
express
gene
product
anoth
commonli
affect
cellcycl
pathway
glioma
retinoblastoma
proteincyclindepend
kinasescyclindepend
kinas
inhibitor
cdkn
circuit
preliminari
studi
restor
genom
region
glioblastoma
cell
line
demonstr
tumor
growth
arrest
apoptosi
anoth
candid
gene
therapi
approach
epiderm
growthfactor
receptor
gene
show
frequent
amplif
primari
gbm
clinic
trial
use
adenovir
vector
deliv
gene
patient
recurr
gbm
conduct
gene
therapi
approach
use
genet
immun
modul
enhanc
immun
respons
tumor
express
cytokin
lymphokin
frequent
use
cytokin
achiev
genet
immun
modul
tumor
interleukin
il
interferon
granulocytemacrophag
coloni
stimul
factor
sever
studi
perform
infect
tumor
cell
ex
vivo
cytokin
gene
arrest
cell
growth
irradi
reimplant
cell
sustain
paracrin
secret
cytokin
within
tumor
anoth
model
introduc
rv
produc
cell
carri
immun
modul
gene
tumor
infect
occur
situ
sever
phase
trial
current
underway
use
strategi
howev
sever
cn
toxic
report
cytokin
secret
tumor
cell
intracrani
one
clinic
trial
human
recurr
glioma
conduct
av
vector
employ
deliv
gene
human
gene
therapi
also
use
gener
tumor
vaccin
induc
tumor
antigen
present
antigenpres
cell
antigenpres
cell
ie
dendrit
cell
harvest
peripher
blood
brain
tumor
biopsi
specimen
transduc
dna
mrna
andor
protein
code
tumor
antigen
expand
vitro
administr
patient
clinic
trial
use
genebas
approach
gbm
current
process
neovascular
featur
malign
glioma
depend
sever
potent
angiogen
factor
secret
tumor
cell
vascular
endotheli
growth
factor
import
overexpress
angiogen
factor
glioma
shown
vivo
transfer
recombin
av
vector
carri
gene
vascular
endotheli
growth
factor
antisens
orient
glioma
inhibit
tumor
growth
antisens
oligonucleotid
singl
strand
dna
rna
bind
complementari
rna
sequenc
bind
take
place
dnarna
hybrid
degrad
subsequ
prevent
protein
synthesi
anoth
studi
show
signific
glioma
inhibit
use
rv
vector
deliv
signalingdefect
vascular
endotheli
growth
factor
receptor
form
inact
dimer
wildtyp
vascular
endotheli
growth
factor
receptor
addit
one
gene
replac
strategi
describ
earlier
might
also
antiangiogen
effect
due
discoveri
induc
wildtyp
express
astrocytoma
caus
releas
angiogenesi
inhibitori
factor
intens
neovascular
malign
glioma
may
enabl
new
intravascular
modal
gene
therapi
diseas
although
genet
vector
administ
intravascularli
unlik
penetr
bloodbrain
barrier
intravascular
deliveri
vector
may
target
endotheli
cell
brain
far
trial
conduct
use
approach
glioma
sever
method
nonvir
gene
transfer
howev
method
rel
ineffici
capac
transfer
gene
suffici
elev
number
cell
especi
vivo
gene
deliveri
brain
tumor
far
effect
way
transfer
dna
somat
cell
remain
use
viralbas
deliveri
system
vector
brain
tumor
therapi
divid
two
categori
replicationdefect
vector
name
vector
replicationcompet
ie
replicationcondit
oncolyt
virus
name
oncolyt
virus
ov
first
instanc
vector
deriv
viru
viral
gene
remov
minim
virusmedi
toxic
second
instanc
select
viral
gene
delet
mutat
viral
target
andor
replic
occur
select
tumor
versu
endogen
neural
cell
far
replicationdefect
vector
use
gene
therapi
trial
brain
tumor
base
retroviru
av
term
replicationcompet
oncolyt
virus
one
use
clinic
trial
brain
tumor
hsv
av
reoviru
newcastl
diseas
viru
tabl
howev
experiment
almost
type
viru
use
either
replic
defect
replicationcompet
fashion
retrovirus
retrovirus
rv
class
envelop
virus
contain
singlestrand
rna
mole
rv
primarili
use
vector
although
preclin
studi
like
futur
attempt
clinic
trial
use
retroviralbas
ov
recent
replicationcompet
retrovir
rcr
vector
base
moloney
murin
leukemia
viru
found
replic
kinet
similar
wildtyp
moloney
murin
leukemia
viru
also
found
stabl
multipl
serial
passag
cultur
cell
inject
rcr
vector
establish
subcutan
intracrani
tumor
mice
result
highli
effici
transmiss
transgen
case
result
transduct
entir
tumor
follow
vector
system
test
preclin
studi
rcrhsvtkganciclovir
one
rcrcd
vector
develop
possibl
use
clinic
trial
tocagen
inc
advantag
rv
vector
rel
easi
manipul
gene
therapi
purpos
use
wide
avail
longterm
experi
low
toxic
normal
brain
tissu
make
vector
safe
candid
cn
gene
therapi
one
problem
rv
vector
viral
genom
insert
randomli
genom
host
insert
happen
middl
one
host
gene
gene
disrupt
insert
mutagenesi
disrupt
host
gene
involv
regul
cell
divis
uncontrol
cell
divis
ie
cancer
occur
disadvantag
rv
vector
low
titer
instabl
viral
particl
small
transgen
capac
maximum
amount
dna
packag
retroviru
allow
kb
foreign
dna
anoth
drawback
rv
vector
requir
target
cell
divid
integr
express
viral
gene
restrict
gene
therapi
prolifer
cell
although
rv
vector
use
earli
gene
therapi
trial
use
greatli
reduc
recent
gene
therapi
trial
cancer
adenovir
vector
adenovirus
av
nonenvelop
virus
contain
linear
doublestrand
dna
genom
respons
respiratori
eye
infect
human
gene
therapi
purpos
commonli
use
av
vector
deriv
subgroup
manipul
produc
replicationdefici
vector
av
commonli
use
gene
therapi
vector
fact
becom
common
tool
kit
molecular
biolog
lab
whenev
gene
need
express
mammalian
cell
vector
extens
modifi
target
away
usual
receptor
present
cell
receptor
present
desir
target
cell
bound
receptor
viru
enter
cell
endosom
vesicl
fuse
lysosom
viru
abl
liber
escap
cell
nucleu
gene
express
viral
dna
gener
integr
host
genom
surviv
extrachromosom
element
term
gene
deliveri
brain
tumor
vector
use
deliv
almost
type
anticanc
gene
howev
clinic
glioma
trial
avmedi
deliveri
gene
hsvtk
human
publish
far
summari
av
use
wide
vector
gene
therapi
trial
advantag
use
rel
eas
manipul
abil
produc
high
titer
furthermor
av
vector
effici
transduc
wide
varieti
cell
divid
nondivid
vitro
vivo
av
usual
integr
genet
materi
host
genom
rather
replic
episom
element
nucleu
host
cell
transient
gene
express
consequ
risk
insert
mutagenesi
limit
av
vector
shortterm
gene
express
product
toxic
acutephas
respons
clinic
trial
begun
progress
becom
appar
av
vector
may
caus
signific
innat
immun
respons
oncolyt
adenoviru
oncolyt
av
engin
natur
occur
strain
viru
replic
better
tumor
cell
versu
normal
cell
select
occur
three
gener
level
first
everi
time
viru
infect
cell
antivir
respons
occur
insid
cell
consist
numer
stress
signal
fig
overal
effect
signal
limit
abil
infect
viru
replic
thu
limit
number
viral
progeni
could
go
infect
neighbor
cell
stress
signal
consist
gene
involv
pathway
nfkb
tolllik
receptor
respons
pkr
other
case
tumor
cell
disabl
respons
respons
tend
proapoptot
antiprolif
therefor
tumor
cell
disabl
respons
provid
better
target
viral
replic
normal
cell
intact
antivir
respons
second
tumor
cell
sever
gene
involv
cellcycl
regul
apoptosi
signal
disrupt
disrupt
tumor
cell
factor
exploit
ration
engin
viral
mutant
replic
well
normal
cell
intact
cellcycleapoptosi
control
replic
tumor
cell
harbor
disrupt
final
viral
mutant
reengin
target
cell
surfac
receptor
present
tumor
versu
normal
cell
instanc
engin
oncolyt
adenoviru
name
lack
viral
gene
encod
protein
inactiv
cellular
tumor
suppressor
protein
mutant
av
believ
replic
lyse
human
tumor
cell
cell
function
base
gene
mutat
vector
could
use
much
human
gbm
carri
mutat
may
poss
anticanc
effect
remain
tumor
function
modul
arf
protein
gene
frequent
delet
gbm
howev
subsequ
experi
viru
reveal
mechan
tumor
select
base
lack
tumor
suppressor
function
rather
complic
mechan
relat
nuclear
export
viral
mrna
tumor
cell
oncolyt
av
includ
target
defect
tumor
suppressor
pathway
protein
share
gene
region
arf
make
one
commonli
mutat
side
glioma
envelop
neurotrop
dna
viru
wild
type
abl
proceed
lytic
life
cycl
infect
persist
intranuclear
episom
latent
state
interest
use
cancer
attack
agent
becam
high
report
show
genet
engin
form
oncolyt
brain
tumor
model
sinc
numer
report
detail
variou
type
genet
engin
mutant
glioma
therapi
two
commonli
use
type
revolv
around
delet
viral
gene
encod
viral
protein
protein
possess
function
ribonucleotid
reductas
recent
report
link
defect
abil
replic
select
cell
defect
tumor
suppressor
gene
type
focus
mutat
viral
gene
encod
viral
protein
viral
gene
counteract
host
cell
respons
base
pkr
enzym
promot
cellular
apoptosi
infect
mechan
tumor
select
mutant
viru
elicit
sever
report
one
case
author
link
viral
defect
enhanc
replic
tumor
cell
elev
level
ra
activ
howev
other
disput
claim
link
mutant
ov
replic
activ
mek
pathway
present
tumor
normal
cell
addit
also
possibl
tumor
cell
may
lost
pkr
function
thu
enabl
mutant
viru
replic
anoth
genet
engin
term
design
replic
compet
gbm
attenu
neurovirul
temperatur
sensit
elimin
ganciclovir
possess
delet
viral
gene
encod
thu
may
select
target
cell
defect
overexpress
mek
intraneoplast
inocul
decreas
tumor
growth
prolong
surviv
anim
model
signific
toxic
normal
brain
base
result
two
phase
studi
use
patient
anaplast
astrocytoma
gbm
complet
promis
result
ov
offer
sever
advantag
potenti
incorpor
larg
load
foreign
dna
infect
human
cell
high
effici
low
viral
particletocel
ratio
sensit
antiherpet
agent
ganciclovir
vcv
provid
safeti
mechan
viral
replic
could
elimin
need
fact
never
integr
host
genom
guarante
risk
insert
mutagenesi
pose
rv
vector
issu
howev
major
challeng
work
genet
manipul
difficult
av
due
larg
size
viral
genom
gene
deliveri
could
affect
due
preexist
hsv
immun
host
mani
adult
expos
experi
interest
preclin
develop
biotechnolog
industri
limit
moreov
potenti
neurotox
vector
could
caus
lifethreaten
enceph
primari
infect
reactiv
latent
viru
measl
viru
measl
viru
mv
belong
paramyxovirida
famili
envelop
singl
strand
rna
virus
numer
virus
consid
potenti
cancer
therapeut
includ
edmonston
vaccin
strain
mv
edmonston
vac
gener
mechan
ov
select
ov
viru
matter
infect
cell
brisk
antivir
danger
stress
respons
ensu
involv
multipl
intersect
interconnect
cellular
pathway
promin
interferon
pathway
nfkb
pathway
pkr
doubl
strand
rnadepend
protein
kinas
tolllik
receptor
signal
pathway
combin
effect
pathway
shut
limit
viral
replic
ie
product
viral
progeni
neighbor
cell
becom
target
progeni
tumor
cell
cellular
mechan
may
disrupt
proapoptot
antiprolif
effect
howev
allow
infect
viru
find
environ
propiti
replic
thu
allow
progeni
virus
made
go
infect
neighbor
cell
cine
strain
enter
cell
predominantli
receptor
interact
cellular
surfac
glycoprotein
receptor
frequent
overexpress
tumor
includ
glioma
express
low
level
normal
brain
contrast
wild
type
viru
result
seriou
diseas
vaccin
strain
mv
excel
safeti
record
million
vaccin
dose
administ
measl
test
varieti
cancer
model
includ
glioma
show
signific
biolog
effect
phase
trial
current
conduct
use
mv
recurr
gbm
e
galani
mayo
clinic
person
commun
reoviru
reoviru
small
rna
viru
produc
selflimit
infect
respiratori
intestin
tract
endem
human
popul
newborn
get
expos
strain
viru
discov
replic
cell
overact
ra
pathway
properti
exploit
attempt
defin
safeti
efficaci
profil
viru
clinic
trial
human
gbm
well
cancer
rna
virus
reovirus
replic
high
level
infect
cell
thu
theori
could
provid
increas
therapeut
punch
larg
number
viral
progeni
could
infect
larg
number
neighbor
tumor
cell
issu
limit
use
viru
relat
small
size
virolog
properti
render
genet
manipul
difficult
rna
virus
also
notori
highli
mutabl
also
problemat
product
use
clinic
experi
current
support
one
biotechnolog
ventur
oncolyt
biotech
inc
calgari
alberta
canada
newcastl
diseas
viru
ndv
viru
ndv
avian
rna
viru
sever
strain
adapt
growth
tumor
cell
phase
trial
intraven
infus
oncolyt
ndv
mutant
glioma
patient
report
advantag
disadvantag
viru
similar
reoviru
howev
differ
viru
exist
immun
avian
viru
exist
human
thu
initi
administr
viru
would
limit
adapt
arm
host
immun
reaction
could
also
disadvantag
zoonot
natur
viru
administr
human
speci
could
gener
mutant
speci
becom
adapt
human
infect
caus
rapid
pandem
occur
past
coronavirus
hiv
mechan
select
viru
tumor
cell
also
well
understood
may
due
impair
andor
host
cell
antivir
respons
tumor
versu
normal
cell
six
virus
two
replicationdefici
four
replic
studi
clinic
brain
tumor
trial
result
publish
eg
replicationdefici
retroviru
replicationdefici
adenoviru
replic
adenoviru
replic
replic
reoviru
replic
ndv
one
replic
viru
measl
studi
glioma
patient
trial
still
ongo
whose
result
yet
publish
rv
av
genet
modifi
express
hsvtk
concurr
gcv
administr
hsv
ndv
use
oncolyt
agent
select
clinic
trial
summar
tabl
first
studi
use
therapi
glioma
patient
use
stereotact
intratumor
inocul
rv
vector
carri
hsvtk
patient
recurr
malign
brain
tumor
although
studi
show
promis
result
term
antitumor
efficaci
control
random
protocol
two
subsequ
phase
ii
studi
patient
recurr
gbm
perform
use
rvhsvtk
approach
follow
gcv
administr
viru
deliv
via
vectorproduc
cell
inject
tumor
resect
first
studi
involv
patient
treatmentrel
advers
effect
note
overal
median
surviv
month
three
patient
surviv
longer
month
one
patient
recurrencefre
year
treatment
compar
intern
multicent
uncontrol
studi
includ
patient
recurr
glioma
median
surviv
time
month
surviv
rate
tumor
recurr
absent
mri
seven
patient
least
month
two
patient
month
one
patient
remain
recurrencefre
month
similar
phase
studi
perform
children
age
year
recurr
malign
supratentori
tumor
studi
also
use
rvhsvtk
gcv
approach
diseas
progress
occur
median
time
month
treatment
longest
time
progress
month
advers
effect
note
larg
control
phase
iii
trial
seem
necessari
ultim
confirm
efficaci
rvhsvtkgcv
approach
studi
use
adjuv
gene
therapi
protocol
standard
therapi
maximum
surgic
resect
irradi
newli
diagnos
gbm
year
followup
patient
divid
gene
therapi
control
arm
surviv
analysi
show
advantag
gene
therapi
term
tumor
progress
overal
surviv
sever
clinic
trial
use
av
vector
malign
glioma
repres
av
trial
briefli
discuss
herein
one
clinic
trial
compar
human
recurr
glioma
treat
direct
stereotact
inject
either
rv
vector
av
vector
express
e
coli
lacz
gene
show
latter
show
widespread
distribut
gene
express
thu
conclud
av
vector
may
superior
abil
distribut
transfer
gene
brain
tumor
phase
iii
trial
evalu
av
vector
express
hsvtk
gene
patient
primari
recurr
highgrad
glioma
studi
perform
control
random
fashion
patient
ie
treatment
arm
control
group
patient
underw
surgic
resect
av
inject
follow
intraven
gcv
postop
day
day
control
group
underw
resect
without
gene
therapi
gcv
inject
median
surviv
gene
therapi
group
significantli
longer
control
group
vs
week
discuss
previous
larg
phase
iii
trial
conduct
europ
israel
agent
cerepro
recent
statement
compani
ark
therapeut
inc
london
unit
kingdom
suggest
evid
efficaci
although
publish
data
would
allow
independ
evalu
claim
recent
phase
trial
avhsvtk
deliv
time
surgic
resect
newli
diagnos
malign
glioma
follow
oral
vcv
combin
standard
therapi
extern
field
radiat
cgi
temozolomid
also
recent
conclud
show
rel
safeti
wherea
data
matur
regard
evid
efficaci
chiocca
et
al
unpublish
data
av
vector
deliv
wildtyp
copi
transgen
also
evalu
human
recurr
glioma
vector
initi
introduc
implant
cathet
place
middl
tumor
bed
follow
resect
tumor
allow
studi
relat
gene
deliveri
distribut
treatment
well
toler
distribut
gene
tumor
rel
low
one
recent
trial
evalu
av
vector
patient
recurr
highgrad
glioma
introduc
stereotact
inject
follow
surgic
resect
addit
inject
vector
tumor
bed
vector
welltoler
one
patient
experienc
confus
postop
inject
believ
caus
local
brain
toxic
tumor
resect
viral
treatment
demonstr
doserel
inflamm
necrosi
suggest
biolog
effect
transfer
gene
next
viru
undergo
clinic
trial
brain
tumor
phase
trial
evalu
safeti
oncolyt
nine
patient
recurr
gbm
direct
intratumor
inject
perform
induct
enceph
advers
clinic
symptom
reactiv
latent
hsv
occur
thu
appear
though
tumor
progress
control
efficaci
investig
oncolyt
mutant
demonstr
vector
nontox
deliv
tumor
adjac
brain
also
shown
explant
glioma
cell
could
still
support
replic
oncolyt
cell
lyse
immedi
rather
shed
low
level
viru
day
lyse
larg
phase
iii
trial
europ
use
conduct
sponsor
crusad
laboratori
wwwcrusadelabscom
anoth
clin
ical
trial
use
differ
mutant
includ
patient
recurr
glioma
similar
result
relat
safeti
rapid
evolut
recombin
dna
technolog
enabl
us
develop
new
therapeut
modal
includ
gene
therapi
howev
screen
new
approach
base
anim
model
far
repres
analog
clinic
scenario
shown
discrep
experiment
anim
studi
clinic
trial
brain
tumor
size
consist
extent
tumor
model
reflect
larg
necrot
infiltr
natur
gbm
approach
aim
immun
enhanc
use
anim
model
poorli
syngen
implant
tumor
unlik
reliabl
predict
human
respons
accordingli
mani
ingeni
gene
therapi
strategi
effect
preclin
studi
may
fulfil
expect
clinic
furthermor
problem
deliveri
genet
vector
solid
brain
tumor
effici
situ
gene
transfer
remain
one
signific
hurdl
gene
therapi
effici
transduct
could
improv
modifi
vectorproduc
cell
migratori
vectorproduc
cell
abil
track
even
singl
tumor
cell
invad
surround
brain
tissu
current
use
manual
inject
vector
limit
volum
inject
given
time
efflux
occur
along
needl
track
might
improv
use
threedimension
neuronavig
techniqu
convectionenhanc
deliveri
method
deliveri
method
involv
infus
therapeut
agent
via
surgic
implant
cathet
use
pressur
gradient
achiev
greater
volum
distribut
compar
evid
diffus
alon
complet
brain
tumor
gene
therapi
trial
offer
promis
result
howev
result
clinic
studi
live
expect
creat
experiment
data
although
gene
deliveri
human
patient
seem
safe
studi
yet
translat
benefit
clinic
present
gene
therapi
studi
trial
brain
tumor
far
avail
outsid
clinic
trial
